DMII Q3 2024 Earnings Report — Drugs Made In America Acquisition II Corp. Ordinary Shares Revenue & Financial Results | Market Cap Arena

Drugs Made In America Acquisition II Corp. Ordinary SharesDMII

Q3 2024 Earnings

Reported September 29, 2024

Quarter Comparison

Revenue

Operating Income

EPS (Diluted)

Metric	Q3 2024	Q2 2024	Q3 2023	QoQ Change	YoY Change
Revenue	$0	—	—	—	—
Op. Income	-$41.7K	—	—	—	—
EPS (Diluted)	$0.00	—	—	—	—

Income Statement

Item	Amount
REVENUE	$0
Cost of Revenue	$0
GROSS PROFIT	$0
R&D Expenses	$0
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$41.7K
Other Expenses	$0
Operating Expenses	$41.7K
Cost & Expenses	$41.7K
OPERATING INCOME	-$41.7K
Interest Income	$0
Interest Expense	$0
Other Income/Expenses	$0
INCOME BEFORE TAX	-$41.7K
Income Tax Expense	$0
Net Income from Continuing Ops	-$41.7K
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$41.7K
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$41.7K
D&A	$0
EBIT	-$41.7K
EBITDA	-$41.7K
EPS	$0
EPS Diluted	$0